BLOCKING THE COMPLEMENT PATHWAY
with a Monoclonal Antibody
By blocking C5, and hence stopping the cascade that leads to C9 drilling a hole in the red cell, ECULIZUMAB,
a humanized anti C5 monoclonal antibody, considerably decreases hemolysis in patients with PNH Paroxysmal
whose red cells lack a surface protein that protects them from the action of "Complement".
Complement is a complex system of proteins that protects us against infection and abnormal cell proliferation.
BREAKING NEWS May 28 2011: Eculizumab life saving in EHEC* (shiga toxin E. coli toxi-infection) cucumber/salad/tomatoes alimentay infection. See the article in NEJM
FOR ALL OTHER INFO ON ENVIRONMENTAL DISEASES, RUSH TO OUR SPECIALIZED PAGES Click here
* or STEC-HUS : shiga toxin producing Eschericia coli Hemolytic Uremic syndrome